Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00. Following the transaction, the insider directly owned 126,019 shares of the company’s stock, valued at approximately $40,418,073.87. This trade represents a 2.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.

Natera Trading Up 0.8%

NTRA traded up $2.50 during trading hours on Thursday, hitting $327.67. The company’s stock had a trading volume of 708,176 shares, compared to its average volume of 1,439,570. The company has a 50-day simple moving average of $291.29 and a 200 day simple moving average of $237.00. The firm has a market capitalization of $47.23 billion, a PE ratio of -240.93 and a beta of 1.54. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $343.18.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.74) earnings per share. Research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on NTRA. TD Cowen raised their target price on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Citigroup raised their price objective on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Royal Bank Of Canada boosted their target price on Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Finally, Robert W. Baird set a $348.00 target price on Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $319.38.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. Trust Co. of Vermont bought a new stake in Natera during the second quarter worth approximately $26,000. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter valued at $29,000. Elevation Wealth Partners LLC bought a new position in shares of Natera in the second quarter valued at $30,000. Palladiem LLC acquired a new stake in shares of Natera during the 4th quarter valued at $31,000. Finally, Horizon Investments LLC acquired a new stake in shares of Natera during the 3rd quarter valued at $32,000. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.